Cisapride versus placebo in reflux esophagitis: A multicenter double-blind trial

Journal of Clinical Gastroenterology

Volumn 10, Issue 6, 1988, Pages 614-618

  Baldi, F ^a   Porro, G Bianchi ^b   Dobrilla, G ^c   Iascone, C ^d   Lobello, R ^e   Marzio, L ^f   Sabbatini, F ^g   Tittobello, A ^h   Verme, G ⁱ  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CENTRAL HOSPITAL OF BOLZANO   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Ss Annunziata Hospital   (Italy)

^g New Polyclinic ^*  (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ Maggiore Hospital   (Italy)

Author keywords

Antacid; Cisapride; Endoscopy; Placebo; Reflux esophagitis

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; CISAPRIDE;

ANXIETY; BACKACHE; BIOPSY; CONSTIPATION; CONTROLLED STUDY; ENDOSCOPY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REFLUX ESOPHAGITIS; SIDE EFFECT; SOMNOLENCE; ULCER;

ADULT; CISAPRIDE; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; HUMAN; MALE; MIDDLE AGE; MULTICENTER STUDIES; PERISTALSIS; PIPERIDINES; PLACEBOS; RANDOM ALLOCATION;

EID: 0024242678     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/00004836-198812000-00007     Document Type: Article

References (24)

1. Behar J. The role of the lower esophageal sphincter in reflux prevention. J Clin Gastroenterol 1986;8(suppl 1):2-4.
2. Cohen S, Merlo A. Gastroesophageal reflux. Evaluation and current treatment. Postgrad Med 1987;81:203-18.
3. Gill RC, Bowes KL, Murphy PD, Kingma YJ. Esophageal motor-abnormalities in gastroesophageal reflux and the effect of fun-doplication. Gastroenterology 1986;91:364-9.
4. Orlando RC. Esophageal epithelial resistance. J Clin Gastroenterol 1986;8(suppl 1):12-6.
5. Castell DO. Introduction to the pathophysiology of gastroesophageal reflux. In: Castell DO, Wu WC, Ott DJ, eds. Gastro-esoph-ageal reflux disease. Pathogenesis, diagnosis, therapy. New York, Futura Publishing, 1985:3-9.
6. Schuurkes JAJ, Van Nueten JM, Van Daele PGH, Reyntjens AJ, Janssen PAJ. Motor-stimulating properties of cisapride on isolated gastrointestinal preparations of the guinea pig. J Pharmacol Exp Ther 1985;234:775-83.
7. Reyntjens A, Verlinden M, Aerts T. Development and clinical use of the new gastrointestinal prokinetic drug cisapride (R 51 619). Drug Dev Res 1986;8:251-65.
8. Janssens J. Effect of cisapride on oesophageal motility. In: Johnson AG, Lux G, eds. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. Amsterdam: Excerpta Medica, 1988:48-55.
9. Smout AJPM, Bogaard JW, Grade AC, Ten Thije OJ, Akkermans LMA, Wittebol P. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985;26:246-51.
10. Corazziari E, Scopinaro F, Bontempo I, et al. Effect of R 51 619 on distal oesophageal motor activity and gastric emptying. Ital J Gastroenterol 1983;15:185-6.
11. Weiser HF, Hölscher AH, Zimmermann TH. Influence of cisapride on esophageal acid clearance. In: L. Koslowski, ed. Chirurgisches Forum ’84 f. experim. u. klinische Forschung. Berlin: Springer, 1984:131-4.
12. Saye Z, Forget P, Geubelle F. Effect of cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease. Pediatr Pulmonol 1986;3:8-12.
13. Feldman M, Smith HJ. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo. Gastroenterology 1987;92:171-4.
14. Jian R, Ducrot F, Piedeloup C, Mary JY, Najean Y, Bernier JJ. Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). Gut 1985;26:352-8.
15. Horowitz M, Maddox A, Harding PE, et al. The effect of single dose and chronic administration of cisapide on gastric and oesophageal emptying in insulin-dependent diabetes mellitus. Gastroenterology 1987;92:1899-907.
16. Reyntjens A, Verlinden M, De Coster R, et al. Clinical pharmacological evidence for cisapride’s lack of antidopaminergic or direct cholinergic properties. Curr Ther Res 1984;36:1045-52.
17. Verlinden M, Reyntjens A, Schuermans V. Safety profile of cisapride. In: Johnson AG, Lux G, eds. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. Amsterdam: Excerpta Medica, 1988:30-8.
18. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastresophageal reflux in man. Gastroenterology 1970;68:163-74.
19. SAS User’s Guide: Basics, Version 5 Edition. Cary, North Carolina, U.S.A.: SAS Institute, 1985:1290.
20. Reyntjens A. Cisapride in the treatment of gastro-esophageal reflux symptoms. Digestion 1986;34:143.
21. Hüttemann W. Cisapride in the treatment of oesophagitis. A placebo-controlled trial. In: Johnson AG, Lux G, eds. Progress in the treatment of gastrointestinal motility disorders: the role of cisapride. Amsterdam: Excerpta Medica, 1988:56-62.
22. Nicolaidis CA, Kehagioglou K, Mantzaris G, et al. Cisapride relieves reflux symptoms in esophagitis patients. Double-blind placebo-controlled comparison of two dosages. Prog Med 1987;43(suppl 1):43-8.
23. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983;25:451-94.
24. Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs. metoclopramide in the medical treatment of reflux esophagitis. Hepato-enterol 1983;30:96-8.